Mitsubishi Tanabe Pharma Corp (4508.T)
Latest Key Developments (Source: Significant Developments)
Oct 4 (Reuters) - HEALTH CANADA: :HEALTH CANADA APPROVES NEW DRUG TO TREAT PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS).HEALTH CANADA - WILL CONTINUE TO WORK WITH MANUFACTURER TO FACILITATE ACCESS TO EDARAVONE UNTIL AUTHORIZED DRUG IS AVAILABLE ON CANADIAN MARKET. Full Article
April 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Says rating outlook stable -R&I. Full Article
Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement . Full Article
Nov 8 (Reuters) - Kaken Pharmaceutical Co Ltd <4521.T>:Says co signed an exclusive distribution agreement with Tai Tien Pharmaceuticals Co Ltd (Tai Tien), which is a subsidiary of Mitsubishi Tanabe Pharma Corporation <<<4508.T>>>, for the topical formulation for Onychomycosis "Clenafin/Jublia" (product) in Taiwan.According to the agreement, co grants to Tai Tien the exclusive right for sales of the product in Taiwan and Tai Tien expects to launch the product in 2018. Full Article
Oct 18(Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it completed purchase of NeuroDerm Ltd <<
LONDON, Oct 3 Frustrated by delays in new medicines reaching their own country, a small but growing number of patients are turning to an online broker that bills itself as a legal version of the Dallas Buyers Club.